Reviewing InVivo Therapeutics Holdings Corp. (NVIV)’s and Teligent Inc. (NASDAQ:TLGT)’s results

This is a contrast between InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) and Teligent Inc. (NASDAQ:TLGT) based on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InVivo Therapeutics Holdings Corp. N/A 0.00 21.27M -91.64 0.00
Teligent Inc. 64.44M 0.46 40.18M -0.75 0.00

In table 1 we can see InVivo Therapeutics Holdings Corp. and Teligent Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both companies.

Net Margins Return on Equity Return on Assets
InVivo Therapeutics Holdings Corp. 0.00% 0% 0%
Teligent Inc. -62.35% -84.1% -14.9%

Volatility and Risk

A 1.76 beta indicates that InVivo Therapeutics Holdings Corp. is 76.00% more volatile compared to Standard and Poor’s 500. Competitively, Teligent Inc.’s 45.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 1.45 beta.

Liquidity

The Current Ratio of InVivo Therapeutics Holdings Corp. is 6.9 while its Quick Ratio stands at 6.9. The Current Ratio of rival Teligent Inc. is 1.5 and its Quick Ratio is has 1. InVivo Therapeutics Holdings Corp. is better equipped to clear short and long-term obligations than Teligent Inc.

Insider and Institutional Ownership

The shares of both InVivo Therapeutics Holdings Corp. and Teligent Inc. are owned by institutional investors at 13.1% and 83.8% respectively. About 0.1% of InVivo Therapeutics Holdings Corp.’s share are owned by insiders. Comparatively, Teligent Inc. has 0.1% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
InVivo Therapeutics Holdings Corp. -9.3% -25.48% -18.18% -41.21% -85.73% -22.52%
Teligent Inc. -0.89% -10.79% -43.54% -72.55% -69.96% -34.88%

For the past year InVivo Therapeutics Holdings Corp. has stronger performance than Teligent Inc.

Summary

On 6 of the 9 factors InVivo Therapeutics Holdings Corp. beats Teligent Inc.

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Teligent, Inc., a specialty generic pharmaceutical company, develops, formulates, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The companyÂ’s products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract formulation and contract manufacturing services comprising formulating, testing, and/or manufacturing prescription drugs and medical devices. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.